Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: A systematic review and meta-analysis

International Journal of Infectious Diseases

Volumn 25, Issue , 2014, Pages 130-135

  Jiang, Hai Yin ^a   Zhang, Min Na ^b   Chen, Hai Jun ^c   Yang, Ying ^a   Deng, Min ^a   Ruan, Bing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c Jinhua Central Hospital   (China)

Author keywords

Efavirenz; HIV; Nevirapine; Rifampin; Tuberculosis

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RIFAMPICIN; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL (TOPIC); CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL DISEASE; META ANALYSIS; MIXED INFECTION; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; STANDARD; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; IMMUNOLOGY; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS AS TOPIC; COINFECTION; HIV INFECTIONS; HUMANS; NEVIRAPINE; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 84903466310     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.04.020     Document Type: Review

References (36)

1. Hogg R.S., Heath K.V., Yip B., Craib K.J., O'Shaughnessy M.V., Schechter M.T., et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
2. Corbett E.L., Watt C.J., Walker N., Maher D., Williams B.G., Raviglione M.C., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003, 163:1009-1021.
3. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 Revision. Geneva: World Health Organization; 2010.
4. Manosuthi W., Sukasem C., Lueangniyomkul A., Mankatitham W., Thongyen S., Nilkamhang S., et al. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrob Agents Chemother 2013, 57:1019-1024.
5. Sinha S., Dhooria S., Kumar S., Shah N., Velpandian T., Ravi A., et al. The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment. AIDS Res Ther 2011, 8:41.
6. Uttayamakul S., Likanonsakul S., Manosuthi W., Wichukchinda N., Kalambaheti T., Nakayama E.E., et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther 2010, 7:8.
7. Bersoff-Matcha S.J., Rourke D., Blank J. Evaluation of the safety of nevirapine therapy during pregnancy. J Acquir Immune Defic Syndr 2010, 54:560-562.
8. Raboud J.M., Montaner J.S., Conway B., Rae S., Reiss P., Vella S., et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998, 12:1619-1624.
9. Raboud J.M., Rae S., Montaner J.S., Predicting H.I.V. RNA virologic outcome at 52-weeks follow-up in antiretroviral clinical trials. The INCAS and AVANTI Study Groups. J Acquir Immune Defic Syndr 2000, 24:433-439.
10. World Health Organization. Treatment of tuberculosis: guidelines for national programs. 3rd ed. Geneva: WHO; 2003.
11. Demets D.L. Methods for combining randomized clinical trials: strengths and limitations. Stat Med 1987, 6:341-350.
12. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
13. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
14. Padmapriyadarsini C., Bhavani P.K., Tang A., Kumar H., Ponnuraja C., Narendran G., et al. Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. Int J Infect Dis 2013, 17:e1154-e1159.
15. Bonnet M., Baudin E., Jani I.V., Nunes E., Verhoustraten F., Calmy A., et al. Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome. PLoS One 2013, 8:e84585.
16. Sinha S., Raghunandan P., Chandrashekhar R., Sharma S.K., Kumar S., Dhooria S., et al. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. BMC Infect Dis 2013, 13:482.
17. Shipton L.K., Wester C.W., Stock S., Ndwapi N., Gaolathe T., Thior I., et al. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis 2009, 13:360-366.
18. Matteelli A, Kouanda S, Saleri N, Ouedraogo G. Efficacy and safety of nevirapine- vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. Abstract 47462. 20th Conference on Retroviruses and Opportunistic Infections; 2013.
19. Bonnet M., Bhatt N., Baudin E., Silva C., Michon C., Taburet A.M., et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis 2013, 13:303-312.
20. Villar Garcia J., Vallecillo G., Gonzalez-Mena A., Sorli Redo L., Lopez Colomes J.L., Guelar Grimberg A., et al. Nonnucleoside analogue use with rifampicin in HIV-infected patients with tuberculosis. HIV Med 2009, 10:39-40.
21. Swaminathan S., Padmapriyadarsini C., Venkatesan P., Narendran G., Ramesh Kumar S., Iliayas S., et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011, 53:716-724.
22. Manosuthi W., Mankatitham W., Lueangniyomkul A., Chimsuntorn S., Sungkanuparph S. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med 2008, 9:294-299.
23. Boulle A., Van Cutsem G., Cohen K., Hilderbrand K., Mathee S., Abrahams M., et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008, 300:530-539.
24. Manosuthi W., Sungkanuparph S., Tantanathip P., Lueangniyomkul A., Mankatitham W., Prasithsirskul W., et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009, 48:1752-1759.
25. Mbuagbaw L.C., Irlam J.H., Spaulding A., Rutherford G.W., Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst Rev 2010, (12):CD004246.
26. Lalloo U.G. Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas?. Clin Infect Dis 2009, 48:1760-1762.
27. Oudijk J.M., McIlleron H., Mulenga V., Chintu C., Merry C., Walker A.S., et al. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. AIDS 2012, 26:1523-1528.
28. Kwara A., Ramachandran G., Swaminathan S. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Exp Opin Drug Metab Toxicol 2010, 6:55-68.
29. Maartens G., Decloedt E., Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009, 14:1039-1043.
30. Bonnet M, Jani IV. Pharmacokinetics of nevirapine in tuberculosis-HIV co-infected patients receiving rifampicin ANRS12146 (CARINEMO). International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009.
31. Pillay P., Ford N., Shubber Z., Ferrand R.A. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS One 2013, 8:e68995.
32. Elsherbiny D., Cohen K., Jansson B., Smith P., McIlleron H., Simonsson U.S. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur J Clin Pharmacol 2009, 65:71-80.
33. Okwera A., Whalen C., Byekwaso F., Vjecha M., Johnson J., Huebner R., et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration. Lancet 1994, 344:1323-1328.
34. Lawn S.D., Bekker L.G., Miller R.F. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005, 5:361-373.
35. Koole O., Colebunders R. Reducing mortality from HIV infection and tuberculosis. Lancet Infect Dis 2011, 11:494-495.
36. Kenedi C.A., Goforth H.W. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav 2011, 15:1803-1818.